Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study

Executive Summary

In data presented at the Alzheimer's Association International Conference in Copenhagen, held July 12-17, Roche’s anti-amyloid beta antibody misses endpoints in two Phase II studies, but there were some promising signs of efficacy.


Related Content

ApoE Mounts A Comeback In Alzheimer’s
Genentech Seeks Partners For Biomarker-Driven Drug Development Beyond Oncology
What’s Ahead For Roche In 2015
Lilly Amyvid Lawsuit: CMS Used Tougher Standard For Alzheimer's Scan
Tau Interest Rising As Janssen Licenses AC Immune Alzheimer’s Vaccine
Lilly Back In The BACE Space Following Deal With AstraZeneca
Roche Not Ruling Out Creative Deals For ‘Tail End’ Brands
A New Direction For Alzheimer’s R&D: FDA Outlines Early Disease Pathway
Beyond A-Beta: New Approaches To Alzheimer’s
Advisory Committee Set To Review Cardiovascular Risk Assessment For Obesity Drugs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts